Should I buy or sell Oculis stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oculis in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OCS shares. View OCS analyst ratings or view top-rated stocks .

What is Oculis' stock price target for 2024?

8 analysts have issued twelve-month price targets for Oculis' stock. Their OCS share price targets range from $23.00 to $64.00. On average, they predict the company's stock price to reach $34.00 in the next year. This suggests a possible upside of 240.3% from the stock's current price. View analysts price targets for OCS or view top-rated stocks among Wall Street analysts .

How have OCS shares performed in 2023?

Oculis' stock was trading at $9.2122 at the beginning of the year. Since then, OCS shares have increased by 8.4% and is now trading at $9.99. View the best growth stocks for 2023 here .

When is Oculis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024. View our OCS earnings forecast .

How were Oculis' earnings last quarter?

Oculis Holding AG (NASDAQ:OCS) posted its quarterly earnings results on Wednesday, November, 15th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.02. The business earned $0.25 million during the quarter, compared to analysts' expectations of $0.30 million.

Who are Oculis' major shareholders?

Oculis' stock is owned by many different institutional and retail investors. Top institutional investors include Pivotal bioVenture Partners Investment Advisor LLC (6.10%), Nan Fung Group Holdings Ltd (1.67%) and Wolverine Asset Management LLC (0.02%).

How do I buy shares of Oculis?

Shares of OCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Oculis Stock Price, News & Analysis (NASDAQ:OCS)

$9.99

+0.17 (+1.73%)

(As of 12/1/2023 ET)

Compare

Today's Range: $9.90
▼
$10.35
50-Day Range: $9.10
▼
$11.75
52-Week Range: $6.26
▼
$14.50

Volume: 3,547 shs
Average Volume: 17,165 shs
Market Capitalization: $363.54 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $34.00

Oculis MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 240.3% Upside
$34.00 Price Target
Short Interest: Healthy
0.12% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.36
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.97) to ($1.59) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

405th out of 951 stocks

Pharmaceutical Preparations Industry

173rd out of 431 stocks

3.5

Analyst's Opinion

Consensus Rating
Oculis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $34.00, Oculis has a forecasted upside of 240.3% from its current price of $9.99.
Amount of Analyst Coverage
Oculis has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.12% of the float of Oculis has been sold short.
Short Interest Ratio / Days to Cover
Oculis has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Oculis has recently decreased by 10.15%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Oculis does not currently pay a dividend.
Dividend Growth
Oculis does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OCS.

3.0

News and Social Media Coverage

News Sentiment
Oculis has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Oculis this week, compared to 1 article on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Oculis insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 14.28% of the stock of Oculis is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Oculis are expected to grow in the coming year, from ($2.97) to ($1.59) per share.
Price to Book Value per Share Ratio
Oculis has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Oculis Stock (NASDAQ:OCS)

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

OCS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OCS Stock News Headlines

November 30, 2023 | finance.yahoo.com

Oculis Holding AG's (NASDAQ:OCS) top owners are individual investors with 48% stake, while 30% is held by private equity firms

November 17, 2023 | markets.businessinsider.com

Buy Rating for Oculis Holding’s Stock: Promising Pipeline Developments and Financial Health Bolster Positive Outlook

December 3, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 17, 2023 | markets.businessinsider.com

Wedbush Reaffirms Their Buy Rating on Oculis Holding (OCS)

November 15, 2023 | finanznachrichten.de

Oculis Holding AG: Oculis Reports Q3 2023 Financial Results and Provides Company Update

November 15, 2023 | finanznachrichten.de

Oculis Operations Sarl: Oculis Reports Q3 2023 Financial Results and Provides Company Update

November 15, 2023 | finance.yahoo.com

Oculis Reports Q3 2023 Financial Results and Provides Company Update

November 8, 2023 | finance.yahoo.com

Oculis to Present at Upcoming November Investor Conferences

December 3, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 1, 2023 | finance.yahoo.com

Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema

October 10, 2023 | finance.yahoo.com

Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress

October 5, 2023 | msn.com

Stifel Initiates Coverage of Oculis Holding (OCS) with Buy Recommendation

October 5, 2023 | markets.businessinsider.com

What 4 Analyst Ratings Have To Say About Oculis Holding

October 5, 2023 | finance.yahoo.com

Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema

September 24, 2023 | barrons.com

Oculis Holding AG Wt

September 14, 2023 | investing.com

Oculis Holding AG (OCS)

September 11, 2023 | finance.yahoo.com

Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase

August 30, 2023 | msn.com

B of A Securities Maintains Oculis Holding (OCS) Buy Recommendation

August 30, 2023 | markets.businessinsider.com

Expert Ratings for Oculis Holding

August 30, 2023 | finance.yahoo.com

Oculis to Present at Upcoming September Investor Conferences

August 29, 2023 | finanznachrichten.de

Oculis Holding AG: Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update

August 29, 2023 | finance.yahoo.com

Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update

August 17, 2023 | msn.com

Oculis: Swiss Pharma With Excellent Data, Unclear Fundamentals

August 8, 2023 | finance.yahoo.com

OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery

August 4, 2023 | msn.com

HC Wainwright & Co. Reiterates Oculis Holding (OCS) Buy Recommendation

August 3, 2023 | msn.com

Oculis enrols first patient in trial of its OCS-01 eye drops

August 2, 2023 | finance.yahoo.com

First Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema

See More Headlines

Receive OCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oculis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2023
Today: 12/02/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:OCS
CUSIP: N/A
CIK: 1953530
Web: www.oculis.com
Phone: 41-21-711-3970
Fax: N/A
Employees: 28
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $34.00
High Stock Price Target: $64.00
Low Stock Price Target: $23.00
Potential Upside/Downside: +240.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 5.21
Quick Ratio: 5.21

Sales & Book Value

Annual Sales: $960,000.00
Price / Sales: 378.68
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.28 per share
Price / Book: 3.05

Miscellaneous

Outstanding Shares: 36,390,000
Free Float: N/A
Market Cap: $363.54 million
Optionable: Not Optionable
Beta: N/A

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Riad Sherif M.B.A. (Age 55)
M.D., CEO & Director
Ms. Sylvia Cheung (Age 48)
Chief Financial Officer
Mr. Weibo Ding (Age 52)
Global COO & GM of China
Dr. Bastian Dehmel (Age 52)
Chief Development Officer & Head of Development
Dr. Joanne Chang M.D. (Age 62)
Ph.D., Head of Medical Affairs & Chief Medical Officer
Mr. Páll Ragnar Jóhannesson (Age 42)
Chief Strategy Officer
Dr. Fang Li
Senior Vice President of Regulatory Affairs
Ms. Rebecca Weil
Chief Commercial Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

OCS Stock Analysis - Frequently Asked Questions

Should I buy or sell Oculis stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oculis in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OCS shares.
View OCS analyst ratings or view top-rated stocks.
What is Oculis' stock price target for 2024?: 8 analysts have issued twelve-month price targets for Oculis' stock. Their OCS share price targets range from $23.00 to $64.00. On average, they predict the company's stock price to reach $34.00 in the next year. This suggests a possible upside of 240.3% from the stock's current price.
View analysts price targets for OCS or view top-rated stocks among Wall Street analysts.
How have OCS shares performed in 2023?: Oculis' stock was trading at $9.2122 at the beginning of the year. Since then, OCS shares have increased by 8.4% and is now trading at $9.99.
View the best growth stocks for 2023 here.
When is Oculis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024.
View our OCS earnings forecast.

How were Oculis' earnings last quarter?: Oculis Holding AG (NASDAQ:OCS) posted its quarterly earnings results on Wednesday, November, 15th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.02. The business earned $0.25 million during the quarter, compared to analysts' expectations of $0.30 million.
Who are Oculis' major shareholders?: Oculis' stock is owned by many different institutional and retail investors. Top institutional investors include Pivotal bioVenture Partners Investment Advisor LLC (6.10%), Nan Fung Group Holdings Ltd (1.67%) and Wolverine Asset Management LLC (0.02%).
How do I buy shares of Oculis?: Shares of OCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:OCS) was last updated on 12/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial